WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the fourth quarter and full year ended December 31, 2023.
| Twelve Months Ended December 31, | |||||||
| Key Performance Indicators (KPIs)* | 2023 | 2022 | |||||
| Average revenue per top 20 pharmaceutical manufacturer | $ | 2,566,832 | $ | 2,136,746 | |||
| Percent of top 20 pharmaceutical manufacturers that are customers | 90 | % | 90 | % | |||
| Percent of total revenue attributable to top 20 pharmaceutical manufacturers | 65 | % | 62 | % | |||
| Net revenue retention | 105 | % | 90 | % | |||
| Revenue per average full-time employee | $ | 586,242 | $ | 606,312 | |||
Will Febbo, OptimizeRx CEO commented, "Q4 of 2023 ended strongly, setting the Company up well for 2024. Our revenue for the quarter exceeded expectations, reaching $28.4 million, a 44% increase year-over-year. This was fueled by organic growth through our Dynamic Audience Activation Platform (DAAP) and a two-month contribution from the Medicx Health acquisition. Notably, our core HCP business saw an over 30% growth compared to Q4 2022.
I'm extremely proud of everything we accomplished last year. DAAP deals quadrupled to 24, aligning with our strategic goals and providing a solid revenue base and momentum for 2024. Meanwhile, the acquisition of Medicx Health merged a leading Direct-to-Consumer (DTC) audience activation and messaging execution business with our HCP-focused, omnichannel, digital point-of-care pharma marketing business, unlocking new markets and cross-selling opportunities.
Additionally, we successfully completed our operational realignment to focus on core business lines and streamlining our operations to align with our profitable growth strategy."
Financial Highlights
Financial Outlook
For the full year 2024, the Company is reiterating its 2024 guidance and expects revenue to be at least $100 million with an Adjusted EBITDA of at least $11 million.
Definition and Use of Non-GAAP Financial Measures
This earnings release includes a presentation of non-GAAP net income (loss) and non-GAAP net income (loss) per diluted share or non-GAAP EPS, Adjusted EBITDA, all of which are non-GAAP financial measures.
The Company defines non-GAAP net income (loss) as GAAP net income (loss) with an adjustment to add back depreciation, amortization, amortization of debt issuance costs, stock-based compensation, acquisition expenses, severance expense related to a reduction in force, income or loss related to the fair value of contingent consideration, gain or loss from the disposal of a business, asset impairment charges, other income (loss), and deferred income taxes. Non-GAAP EPS is defined as non-GAAP net income (loss) divided by the number of weighted average shares outstanding on a diluted basis. Adjusted EBITDA is defined as GAAP net income (loss) with an adjustment to add back depreciation, amortization, interest, stock-based compensation, acquisition expenses, severance expense related to a reduction in force, income or loss related to the fair value of contingent consideration, gain or loss from the disposal of a business, asset impairment charges, other income (loss), and deferred income taxes. The Company has provided non-GAAP financial measures to aid investors in better understanding its performance. Management believes that these non-GAAP financial measures provide additional insight into the operations and cash flow of the Company.
Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a Company’s non-cash operating expenses, management believes that providing non-GAAP financial measures that exclude non-cash expenses allows for meaningful comparisons between the Company’s business operating results and those of other companies, as well as provides an important tool for financial and operational decision making and for evaluating the Company’s business operating results over different periods of time.
The Company’s non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company’s industry, as other companies in the industry may calculate such non-GAAP financial results differently. The Company’s non-GAAP net income (loss), non-GAAP EPS and Adjusted EBITDA are not measurements of financial performance under GAAP and should not be considered as an alternative to operating income or as an indication of operating performance or any other measure of performance derived in accordance with GAAP. The Company does not consider these non-GAAP measures to be substitutes for or superior to the information provided by its GAAP financial results.
The table, “Reconciliation of Non-GAAP to GAAP Financial Measures,” included below, provides a reconciliation of Non-GAAP net income, Non-GAAP EPS and Adjusted EBITDA for the fourth quarter and full year ended December 31, 2023 and 2022. Although the Company provides guidance for Adjusted EBITDA, it is not able to provide guidance to the most directly comparable GAAP measures. Reconciliations for forward-looking figures would require unreasonable efforts at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance of the unavailable information.
Definition of Key Performance Indicators*
Top 20 pharmaceutical manufacturers: Top 20 pharmaceutical manufacturers are based on Fierce Pharma’s “The top 20 pharma companies by 2022 revenue.” We previously used “The top 20 pharma companies by 2020 revenue”. As a result of this change, prior periods have been restated for comparative purposes.
Net revenue retention: Net revenue retention is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year).
Revenue per average full-time employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount at the end of the most recent period.
About OptimizeRx
OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over two million of U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on their medications.
For more information, follow the Company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, future performance, expected revenues, expected Adjusted EBITDA and prospects. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, seasonal trends, our ability to maintain our contracts with electronic prescription platforms, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.
OptimizeRx Contact
Andy D’Silva, SVP Corporate Finance
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| OPTIMIZERx CORPORATION CONSOLIDATED BALANCE SHEETS | |||||||
| December 31, | |||||||
| 2023 | 2022 | ||||||
| ASSETS | |||||||
| Current Assets | |||||||
| Cash and cash equivalents | $ | 13,852,456 | $ | 18,208,685 | |||
| Short-term investments | — | 55,931,821 | |||||
| Accounts receivable, net of allowance for credit losses of $239,172 and $352,043 at December 31 2023 and 2022, respectively | 36,253,214 | 22,155,301 | |||||
| Taxes receivable | 1,035,754 | — | |||||
| Prepaid expenses and other | 3,189,468 | 2,280,828 | |||||
| Total Current Assets | 54,330,892 | 98,576,635 | |||||
| Property and equipment, net | 149,407 | 137,448 | |||||
| Other Assets | |||||||
| Goodwill | 78,357,074 | 22,673,820 | |||||
| Patent rights, net | 6,184,742 | 1,940,178 | |||||
| Technology assets, net | 9,012,756 | 7,702,895 | |||||
| Tradename and customer relationships, net | 34,198,084 | 3,379,838 | |||||
| Operating lease right-of-use assets | 572,895 | 235,320 | |||||
| Security deposits and other assets | 568,048 | 5,051 | |||||
| Total Other Assets | 128,893,599 | 35,937,102 | |||||
| TOTAL ASSETS | $ | 183,373,898 | $ | 134,651,185 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current Liabilities | |||||||
| Current portion of long-term debt | $ | 2,000,000 | $ | — | |||
| Accounts payable – trade | 2,227,177 | 1,549,979 | |||||
| Accrued expenses | 7,754,781 | 2,601,246 | |||||
| Revenue share payable | 5,505,701 | 3,990,440 | |||||
| Current portion of lease liabilities | 221,625 | 89,902 | |||||
| Deferred revenue | 171,841 | 164,309 | |||||
| Total Current Liabilities | 17,881,125 | 8,395,876 | |||||
| Non-Current Liabilities | |||||||
| Long-term debt, net | 34,230,737 | — | |||||
| Lease liabilities, net of current portion | 371,438 | 144,532 | |||||
| Deferred tax liabilities, net | 4,337,424 | — | |||||
| Total Liabilities | 56,820,724 | 8,540,408 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ Equity | |||||||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2023 and 2022, respectively | — | — | |||||
| Common stock, $0.001 par value, 166,666,667 shares authorized, 19,899,679 and 18,288,571 shares issued at December 31, 2023 and 2022, respectively | 19,899 | 18,289 | |||||
| Treasury stock, $0.001 par value, 1,741,397 and 1,214,398 purchased at December 31, 2023 and 2022, respectively | (1,741 | ) | (1,214 | ) | |||
| Additional paid-in-capital | 190,792,980 | 172,785,800 | |||||
| Accumulated deficit | (64,257,964 | ) | (46,692,098 | ) | |||
| Total Stockholders’ Equity | $ | 126,553,174 | $ | 126,110,777 | |||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 183,373,898 | $ | 134,651,185 | |||
| OPTIMIZERx CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| For the three months ended December 31, | For the year ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Net revenue | $ | 28,368,946 | $ | 19,654,457 | $ | 71,521,506 | $ | 62,450,156 | |||||||
| Cost of revenues, exclusive of depreciation and amortization presented separately below | 10,527,640 | 7,200,029 | 28,621,589 | 23,483,336 | |||||||||||
| Gross margin | 17,841,306 | 12,454,428 | 42,899,917 | 38,966,820 | |||||||||||
| Operating Expenses | |||||||||||||||
| Stock-based compensation | 2,627,480 | 4,269,160 | 13,717,333 | 15,745,822 | |||||||||||
| Loss on disposal of a business | 2,142,319 | — | 2,142,319 | — | |||||||||||
| Depreciation and amortization | 1,006,228 | 456,545 | 2,401,628 | 2,022,029 | |||||||||||
| Impairment charges | 6,737,580 | — | 6,737,580 | — | |||||||||||
| Other sales, general and administrative expenses | 16,230,872 | 8,593,070 | 44,302,771 | 33,489,707 | |||||||||||
| Total operating expenses | 28,744,479 | 13,318,775 | 69,301,631 | 51,257,558 | |||||||||||
| Loss from operations | (10,903,173 | ) | (864,347 | ) | (26,401,714 | ) | (12,290,738 | ) | |||||||
| Other income (expense) | |||||||||||||||
| Interest expense | (1,453,764 | ) | — | (1,453,764 | ) | — | |||||||||
| Other income | 500,001 | — | 500,001 | — | |||||||||||
| Interest income | 117,608 | 538,511 | 2,191,689 | 852,298 | |||||||||||
| Total other income (expense), net | (836,155 | ) | 538,511 | 1,237,926 | 852,298 | ||||||||||
| Loss before provision for income taxes | (11,739,328 | ) | (325,836 | ) | (25,163,788 | ) | (11,438,440 | ) | |||||||
| Income tax benefit | 7,597,922 | — | 7,597,922 | — | |||||||||||
| Net loss | $ | (4,141,406 | ) | $ | (325,836 | ) | $ | (17,565,866 | ) | $ | (11,438,440 | ) | |||
| Weighted average number of shares outstanding – basic | 17,769,670 | 17,159,971 | 17,124,801 | 17,783,992 | |||||||||||
| Weighted average number of shares outstanding – diluted | 17,769,670 | 17,159,971 | 17,124,801 | 17,783,992 | |||||||||||
| Loss per share – basic | $ | (0.23 | ) | $ | (0.02 | ) | $ | (1.03 | ) | $ | (0.64 | ) | |||
| Loss per share – diluted | $ | (0.23 | ) | $ | (0.02 | ) | $ | (1.03 | ) | $ | (0.64 | ) | |||
| OPTIMIZERx CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| For the year ended December 31, | |||||||
| 2023 | 2022 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
| Net loss | $ | (17,565,866 | ) | $ | (11,438,440 | ) | |
| Adjustments to reconcile net loss to net cash (used in) / provided by operating activities: | |||||||
| Depreciation and amortization | 2,401,628 | 2,022,029 | |||||
| Asset impairment charges | 6,737,580 | — | |||||
| Loss on disposal of business | 2,142,319 | — | |||||
| Increase in bad debt expense | 665,973 | 363,512 | |||||
| Stock-based compensation | 13,717,333 | 15,745,822 | |||||
| Amortization of debt issuance costs | 210,737 | — | |||||
| Change in operating assets and liabilities, net of the effects of acquisitions: | |||||||
| Accounts receivable | (8,712,954 | ) | 2,281,773 | ||||
| Prepaid expenses and other assets | (573,333 | ) | 2,650,951 | ||||
| Accounts payable | (1,320,150 | ) | 943,171 | ||||
| Revenue share payable | 1,515,262 | (387,776 | ) | ||||
| Accrued expenses and other liabilities | 1,305,164 | (301,366 | ) | ||||
| Deferred tax liabilities | (7,695,374 | ) | — | ||||
| Deferred revenue | (67,472 | ) | (1,225,598 | ) | |||
| NET CASH (USED IN) / PROVIDED BY OPERATING ACTIVITIES | (7,239,153 | ) | 10,654,078 | ||||
| CASH FLOWS USED IN INVESTING ACTIVITIES: | |||||||
| Purchases of property and equipment | (87,073 | ) | (81,005 | ) | |||
| Proceeds from sale of property and equipment | 10,000 | — | |||||
| Cash paid for acquisitions, net of cash acquired | (82,947,264 | ) | (2,000,000 | ) | |||
| Proceeds from sale of business | 2,540,000 | — | |||||
| Purchase of short-term investments | (162,777,510 | ) | (55,931,821 | ) | |||
| Redemptions of short-term investments | 218,709,331 | — | |||||
| Capitalized software development costs and other | (784,349 | ) | (163,560 | ) | |||
| NET CASH USED IN INVESTING ACTIVITIES | (25,336,865 | ) | (58,176,386 | ) | |||
| CASH FLOWS (USED IN ) / PROVIDED BY FINANCING ACTIVITIES: | |||||||
| Proceeds from long-term debt, net of issuance costs | 37,730,000 | — | |||||
| Repayment of long-term debt | (1,710,000 | ) | — | ||||
| Repurchase of common stock | (7,522,426 | ) | (20,024,258 | ) | |||
| Proceeds from exercise of stock options, net of cash paid for withholding taxes | (277,785 | ) | 1,073,481 | ||||
| NET CASH PROVIDED BY/(USED IN) FINANCING ACTIVITIES | 28,219,789 | (18,950,777 | ) | ||||
| NET DECREASE IN CASH AND CASH EQUIVALENTS | (4,356,229 | ) | (66,473,085 | ) | |||
| CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD | 18,208,685 | 84,681,770 | |||||
| CASH AND CASH EQUIVALENTS – END OF PERIOD | $ | 13,852,456 | $ | 18,208,685 | |||
| SUPPLEMENTAL CASH FLOW INFORMATION: | |||||||
| Cash paid for interest | $ | 1,212,619 | $ | — | |||
| ROU assets obtained in exchange for lease obligations | $ | 459,580 | $ | — | |||
| Reduction of EvinceMed purchase price for amounts previously paid | $ | — | $ | 708,334 | |||
| Shares issued in connection with acquisition | $ | 12,091,142 | $ | 9,374,455 | |||
| Cash paid for income taxes | $ | 48,222 | $ | — | |||
| OPTIMIZERx CORPORATION RECONCILIATION of NON-GAAP to GAAP FINANCIAL MEASURES | |||||||||||||||
| For the Three Months Ended December 31, | For the Twelve Months Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Net (Loss) Income | $ | (4,141,406 | ) | $ | (325,836 | ) | $ | (17,565,866 | ) | $ | (11,438,440 | ) | |||
| Valuation Allowance reversal | (7,695,374 | ) | — | (7,695,374 | ) | — | |||||||||
| Depreciation and amortization | 1,006,227 | 456,545 | 2,401,627 | 2,022,029 | |||||||||||
| Stock-based compensation | 2,627,480 | 4,269,160 | 13,717,333 | 15,745,822 | |||||||||||
| Asset impairment charges | 6,737,580 | — | 6,737,580 | — | |||||||||||
| Loss on disposal of business | 2,142,319 | — | 2,142,319 | — | |||||||||||
| Severance charges | 288,204 | — | 494,681 | — | |||||||||||
| Other income | (500,001 | ) | — | (500,001 | ) | — | |||||||||
| Amortization of debt issuance costs | 210,737 | — | 210,737 | — | |||||||||||
| Acquisition expense | 3,901,606 | — | 4,482,297 | 19,739 | |||||||||||
| Non-GAAP net income | 4,577,372 | 4,399,869 | 4,425,333 | 6,349,150 | |||||||||||
| Non-GAAP net income per share | |||||||||||||||
| Diluted | $ | 0.26 | $ | 0.25 | $ | 0.26 | $ | 0.35 | |||||||
| Weighted average shares outstanding: | |||||||||||||||
| Diluted | 17,789,235 | 17,285,777 | 17,191,300 | 18,048,477 | |||||||||||
| For the Three Months Ended December 31, | For the Twelve Months Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Net (Loss) Income | $ | (4,141,406 | ) | $ | (325,836 | ) | $ | (17,565,866 | ) | $ | (11,438,440 | ) | |||
| Depreciation and amortization | 1,006,227 | 456,545 | 2,401,627 | 2,022,029 | |||||||||||
| Stock-based compensation | 2,627,480 | 4,269,160 | 13,717,333 | 15,745,822 | |||||||||||
| Asset impairment charges | 6,737,580 | — | 6,737,580 | — | |||||||||||
| Loss on disposal of business | 2,142,319 | — | 2,142,319 | — | |||||||||||
| Severance charges | 288,204 | — | 494,681 | — | |||||||||||
| Acquisition expense | 3,901,606 | — | 4,482,297 | 19,739 | |||||||||||
| Other income | (500,001 | ) | — | (500,001 | ) | — | |||||||||
| Net interest (income) expense | 1,336,155 | (538,511 | ) | (737,926 | ) | (852,298 | ) | ||||||||
| Income tax benefit | (7,597,922 | ) | — | (7,597,922 | ) | — | |||||||||
| Adjusted EBITDA | 5,800,242 | 3,861,358 | 3,574,122 | 5,496,852 | |||||||||||
| Last Trade: | US$4.78 |
| Daily Change: | -0.45 -8.60 |
| Daily Volume: | 278,366 |
| Market Cap: | US$88.050M |
November 13, 2024 September 09, 2024 August 08, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
